BioCentury
ARTICLE | Clinical News

MLR-1023: Phase IIa started

April 13, 2015 7:00 AM UTC

Melior began a double-blind, placebo-controlled, U.S. and South Korea Phase IIa trial to evaluate 100 and 200 mg oral MLR-1023 once or twice daily for 4 weeks in about 120 patients. Bukwang Pharmaceu...